The research is some of the first to show that “patient activation” creates more equitable interactions between patients and physicians.

By raising awareness about the correlation between increased radiation exposure and cardiac events, average doses were reduced without minimizing cancer treatment. 

Stopping the interaction between KRAS and the protein AGO2 slowed tumor growth in mouse models.

A 600-patient randomized clinical trial supports pembrolizumab and chemotherapy as a first-line treatment

A new tool that takes into account personalized risks and benefits, and allows for a range of patient preferences, will help clinicians decide whom to screen for lung cancer.